The FibroMeter NAFLD, which estimates the stage of fibrosis based on age, weight, AST, ALT, ferritin, glucose, and platelets values, has been validated in a NAFLD cohort with 235 patients. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.